. Author manuscript; available in PMC: 2018 Jan 26.

Published in final edited form as: Brain Stimul. 2016 May 24;9(5):740–754. doi: 10.1016/j.brs.2016.05.008

Table 2.

Summary of compliance indicated by treatment sessions, study completion and withdrawal rates for sham-tDCS, tDCS, and MHF-tPCS treatment groups.

Group	Number of sessions	Total subjects	Finished trial	Subject that did not meet ongoing inclusion/exclusion criteria				Discomfort
				Atypical headache or migraine		Atypical skin condition		Discomfort
				Between session	Within session	Between session	Within session	Between session	Within session
Sham-tDCS	636	37	33	2	0	2	0	0	0
tDCS	623	33	22	2	0	8	0	0	1
MHF-tPCS	646	30	25	3	0	1	0	0	1
Total	1905	100	80	7	0	11	0	0	2

Subjects who did not meet the ongoing inclusion/exclusion criteria were withdrawn for discomfort, atypical headache and atypical skin condition (see Methods). All other subjects were categorized as “finished trial”. Subjects elected how many sessions to complete over 6 weeks with the minimal requirement of completing four treatment sessions per seven days and a minimal enrollment commitment of 2 weeks.